Iradimed (IRMD) Depreciation & Amortization (CF) (2013 - 2026)

Iradimed (IRMD) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $455000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 134.54% year-over-year to $455000.0 in Q1 2026; TTM through Mar 2026 was $1.4 million, a 81.57% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 42.54% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $455000.0, up from $380680.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for IRMD reached as high as $494176.0 in Q2 2022 and fell as low as -$692905.0 in Q4 2022.
• Historically, Depreciation & Amortization (CF) has averaged $227932.5 across 5 years, with a median of $205375.0 in 2023.
• Across the five-year window, Depreciation & Amortization (CF) tumbled 279.23% in 2022 and soared 134.54% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at -$692905.0 in 2022, then surged by 129.64% to $205375.0 in 2023, then slipped by 4.95% to $195210.0 in 2024, then surged by 95.01% to $380680.0 in 2025, then gained by 19.52% to $455000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $455000.0 in Q1 2026, $380680.0 in Q4 2025, and $383722.0 in Q3 2025.